Please assess the completion status of the following clinical trial:

Trial Title: Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed transitional cell carcinoma of the urinary bladder.~* Metastatic or locally advanced disease.~* No prior chemotherapy.~* Performance status (World Health Organization) 0-2.~* Measurable or evaluable disease.~* Measurable disease is defined as at least 1 unidimensional measurable lesion~  ≥20 mm by conventional techniques or 1 bidimensionally measurable lesion ≥ 20 X 10 mm. Lesions that are smaller or uni- or bidimensionally unmeasurable are considered as evaluable disease.~* Adequate liver (bilirubin ≤ 1.5 Upper Normal Limit, serum glutamate-pyruvate aminotransferase/serum glutamic pyruvic transaminase ≤ 2 Upper Normal Limit, ALP ≤ 2.5 Upper Normal Limit), renal (creatinine ≤ 1.5 Upper Normal Limit) and bone marrow (absolute neutrophil count ≥ 1,500/mm3, platelet count ≥ 100,000/mm3) function.~* Life expectancy \> 3 months.~* Patients must be able to understand the nature of this study and give written informed consent.~Exclusion Criteria:~* History of serious cardiac disease (unstable angina, severe congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias).~* Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer.~* Active infection.~* Uncontrolled inflammation.~* Pregnant or lactating women.~* Psychiatric illness or social situation that would preclude study compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MVAC -\> GEM+CDDP

Based on this trial design, predict the completion outcome and termination type (if applicable).